Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

11 juin 2019 01h48 HE | Source: Genmab A/S

Genmab Signs Agreement with Janssen for Next-Generation CD38 Antibody, HexaBody®-CD38

Company Announcement Genmab signs agreement with Janssen Biotech, Inc. to collaborate exclusively on next-generation CD38 antibody product, HexaBody®-CD38, incorporating Genmab’s proprietary HexaBody...
06 juin 2019 16h38 HE | Source: Genmab A/S

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Company Announcement Copenhagen, Denmark; June 6, 2019 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that at a board meeting the board decided to grant 6,464 restricted stock units and 21,343...
30 mai 2019 17h07 HE | Source: Genmab A/S

U.S. FDA Grants Priority Review for Daratumumab in Combination with Bortezomib, Thalidomide and Dexamethasone in Frontline Multiple Myeloma

Company Announcement U.S. FDA grants Priority Review for daratumumab in combination with bortezomib, thalidomide and dexamethasone as treatment for newly diagnosed patients with multiple myeloma...
28 mai 2019 16h32 HE | Source: Genmab A/S

Genmab Files Registration Statement in the United States for a Proposed Public Offering of American Depositary Shares (ADSs) and Applies for Listing of the ADSs on Nasdaq

Company Announcement Genmab has today filed a registration statement with the U.S. Securities and Exchange Commission for the proposed public offering of ADSs and has applied for listing of the ADSs...
16 mai 2019 09h42 HE | Source: Genmab A/S

Genmab Announces Data to be Presented at 24th EHA Annual Congress

Media Release Copenhagen, Denmark, May 16, 2019 15 industry-sponsored abstracts featuring Genmab programs selected for presentation at EHA Annual Congress Genmab A/S (Nasdaq Copenhagen: GEN)...
14 mai 2019 15h37 HE | Source: Genmab A/S

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement Copenhagen, Denmark; May 14, 2019 – Genmab A/S (Nasdaq Copenhagen: GEN) will increase its share capital by 9,737 shares as a consequence of the exercise of employee warrants. ...
08 mai 2019 11h01 HE | Source: Genmab A/S

Genmab Announces Financial Results for the First Quarter of 2019

May 8, 2019; Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2019 Highlights Regulatory applications for daratumumab in combination with lenalidomide and dexamethasone...
17 avr. 2019 10h52 HE | Source: Genmab A/S

Genmab Announces Data to be Presented at 2019 ASCO Annual Meeting

Media Release Copenhagen, Denmark, April 17, 2019 14 industry sponsored abstracts regarding Genmab programs selected for presentation at ASCO Annual Meeting Genmab A/S (Nasdaq Copenhagen: GEN)...
16 avr. 2019 06h46 HE | Source: Genmab A/S

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2019

Company Announcement Net sales of DARZALEX in the first quarter of 2019 totaled USD 629 millionGenmab will receive royalties on worldwide sales from Janssen Biotech, Inc. Copenhagen, Denmark; April...
05 avr. 2019 01h59 HE | Source: Genmab A/S

Genmab Announces Submission of Supplemental New Drug Application in Japan for Daratumumab in Combination with Lenalidomide and Dexamethasone in Frontline Multiple Myeloma

Media Release Copenhagen, Denmark, April 5, 2019 Supplemental new drug application (sNDA) submitted in Japan for daratumumab in combination with lenalidomide and dexamethasone as treatment for...

Page précédente

Page suivante